Literature DB >> 16093580

Recurrent pancreatitis after trimethoprim-sulfamethoxazole rechallenge.

M W J Versleijen1, A H J Naber, N P Riksen, G J Wanten, F M J Debruyne.   

Abstract

We report a female patient who repeatedly developed pancreatitis after trimethoprim-sulfamethoxazole (TMP/SMX) use. During childhood she had undergone an ureterosigmoidostomy after which she had been on TMP/SMX 480 mg daily as prophylaxis for pyelonephritis for many years. The patient presented with abdominal pain caused by acute pancreatitis. No other cause, except for TMP/SMX use, could be identified. A causal relationship was confirmed by relapse of the pancreatitis after rechallenge. Our case is unique in demonstrating that acute pancreatitis related to the use of TMP/SMX may occur even after long-term treatment. We advise that the medication is discontinued immediately if a causal relationship with pancreatitis is suspected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093580

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  4 in total

1.  A case of recurrent pancreatitis induced by trimethoprim-sulfamethoxazole re-exposure.

Authors:  Tae Young Park; Hyoung-Chul Oh; Jae Hyuk Do
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

Review 2.  Drug-induced pancreatitis : incidence, management and prevention.

Authors:  Anil R Balani; James H Grendell
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations.

Authors:  Dianna Wolfe; Salmaan Kanji; Fatemeh Yazdi; Pauline Barbeau; Danielle Rice; Andrew Beck; Claire Butler; Leila Esmaeilisaraji; Becky Skidmore; David Moher; Brian Hutton
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

4.  Stavudine induced acute necrotizing pancreatitis with tetany in a pediatric patient.

Authors:  Mahendra K Patel; Manish J Barvaliya; Tejas K Patel; C B Tripathi
Journal:  Indian J Pharmacol       Date:  2012 Jul-Aug       Impact factor: 1.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.